Currently browsing: Community News

Assorted News from the Last Week: World Health Organization joins forces with St. Jude Children’s Research Hospital and other key countries to coordinate vital humanitarian action amidst ongoing conflict in the Gaza strip. CAC2 Member Blog by David Achey (Wit You Against Childhood Cancer): "Both during and after treatment, nutrition plays a critical role in supporting the health and well-being of childhood cancer survivors and caregivers.""As a younger physician, I cannot yet seem to curb the feelings of guilt that bubble up when one of my patients dies. In the ever-changing landscape of pediatric oncology, will I always wonder if [...] Read more

Assorted News from the Last Week: While new treatments for leukemia have improved outcomes for many patients, children with Down syndrome have not benefited as much. These young people are at increased risk for acute lymphoblastic leukemia (ALL) and have higher rates of relapse and treatment-related harm. Researchers at the National Cancer Institute (NCI) have developed a way to potentially increase the effectiveness of T cell–based immunotherapy treatments, such as CAR T-cell therapy, against solid tumors. Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased [...] Read more

Assorted News from the Last Week: The US National Childhood Cancer Registry (NCCR) is combining data from myriad sources to hasten and improve research into pediatric and young adult cancers. The registry will also draw information from birth defects registries and state departments of health.   CAC2 Supporting Member Day One Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG). The frequency of cellular therapy trial activations enrolling child/AYA patients with cancer in the U.S. has increased over time. [...] Read more

Assorted News from the Last Week: Trial results confirm effectiveness of Atezolizumab against a rare sarcoma. By a 14-6 vote, the Oncologic Drugs Advisory Committee (ODAC) decided that the totality of evidence presented was sufficient to show that DFMO maintenance improved 2-year event-free survival (EFS). Charles River Laboratories International, Inc. reported that it has the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collection of 400 annotated pediatric cancer models, and is offering clients access to this collection. The combination of apatinib, irinotecan, and temozolomide has shown activity in a phase 2 trial of pediatric and adult patients with [...] Read more

Assorted News from the Last Week: Video distraction minimizes anesthesia for children undergoing radiotherapy. Supporting the family affected by a pediatric cancer diagnosis: siblings matter, too. From the Journal of Clinical Oncology: Chromosomal gains as a favorable prognostic factor in pediatric ALL. A teen's guide to everything cancer. Cancer in kids is different from cancer in grown-ups – figuring out how could lead to better pediatric treatment. Perception of infertility risk mostly inaccurate among young female cancer survivors. Increased surgical duration was found to be an independent risk factor for surgical site infection in patients with lower extremity bone tumors [...] Read more

Assorted News from the Last Week: Opinion piece from the New York Times:  It Takes a Lifetime to Survive Childhood Cancer. (with a bonus that it references a paper from Pediatric Blood Cancer co-authored by several CAC2 Member patient advocates).   Precedent Setting: In a 14 to 6 vote, the FDA’s Oncologic Drug Advisory Committee (ODAC) agrees that eflornithine (DFMO) shows sufficient evidence to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma (HRBN) who are in remission and have completed multi-agent, multi-modality therapy. The Food and Drug Administration (FDA) has approved Bosulif (bosutinib) for the treatment of [...] Read more

Assorted News from the Last Week: On September 26, 2023, the FDA approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed (ND) or resistant or intolerant (R/I) to prior therapy. Comedian Rob Delaney found out his youngest son Henry had brain cancer. This is a story about the saddest of places life can take you, but it's also about the biggest of loves and how to scrape up bits of joy. "How caring for my child with cancer changed my approach to clinical [...] Read more

Assorted News from the Last Week: U.S. Congressman Michael McCaul (R-Texas) and Childhood Cancer Caucus Co-Chairs Ami Bera (D-Calif.) and Mike Kelly (R-Pa.) introduced the Childhood Cancer Clinical Trials Act, legislation to ensure pediatric cancer patients can access and afford clinical trials offering cutting-edge treatment. Among pediatric patients with low-grade glioma with BRAF V600 mutations, dabrafenib plus trametinib resulted in significantly more responses, longer progression-free survival, and a better safety profile than standard chemotherapy as first-line therapy. Acute and long-term psychosocial consequences in grandparents when a grandchild is diagnosed with cancer – the GROKids Project. NCI released its Fiscal Year [...] Read more

Assorted News from the Last Week: White House announces new Cancer Moonshot Initiatives, including several initiatives involving CAC2 Members: xCures, a health-data technology platform, is launching a study to enhance the collection and organization of comprehensive data for Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG). The study will streamline and standardize data gathering and identify patterns that can predict disease progression and treatment response, leading to more personalized treatment plans and targeted therapies. xCures pledges to maintain the data infrastructure for this study, and to make the data freely available to academic and government researchers. This will [...] Read more